全文获取类型
收费全文 | 74750篇 |
免费 | 3898篇 |
国内免费 | 321篇 |
专业分类
耳鼻咽喉 | 1279篇 |
儿科学 | 2298篇 |
妇产科学 | 1974篇 |
基础医学 | 9193篇 |
口腔科学 | 2165篇 |
临床医学 | 5687篇 |
内科学 | 18324篇 |
皮肤病学 | 1677篇 |
神经病学 | 6328篇 |
特种医学 | 2660篇 |
外国民族医学 | 7篇 |
外科学 | 10010篇 |
综合类 | 540篇 |
一般理论 | 22篇 |
预防医学 | 6656篇 |
眼科学 | 1480篇 |
药学 | 4783篇 |
中国医学 | 234篇 |
肿瘤学 | 3652篇 |
出版年
2023年 | 624篇 |
2022年 | 1095篇 |
2021年 | 2317篇 |
2020年 | 1240篇 |
2019年 | 1882篇 |
2018年 | 3979篇 |
2017年 | 2528篇 |
2016年 | 2049篇 |
2015年 | 1944篇 |
2014年 | 2818篇 |
2013年 | 3781篇 |
2012年 | 4981篇 |
2011年 | 5186篇 |
2010年 | 3108篇 |
2009年 | 2558篇 |
2008年 | 3966篇 |
2007年 | 3986篇 |
2006年 | 3775篇 |
2005年 | 3762篇 |
2004年 | 3387篇 |
2003年 | 3225篇 |
2002年 | 3017篇 |
2001年 | 1612篇 |
2000年 | 1669篇 |
1999年 | 1375篇 |
1998年 | 583篇 |
1997年 | 398篇 |
1996年 | 370篇 |
1995年 | 306篇 |
1994年 | 268篇 |
1993年 | 259篇 |
1992年 | 642篇 |
1991年 | 517篇 |
1990年 | 516篇 |
1989年 | 446篇 |
1988年 | 403篇 |
1987年 | 420篇 |
1986年 | 374篇 |
1985年 | 325篇 |
1984年 | 240篇 |
1983年 | 205篇 |
1979年 | 183篇 |
1978年 | 171篇 |
1977年 | 135篇 |
1976年 | 133篇 |
1975年 | 151篇 |
1974年 | 154篇 |
1973年 | 165篇 |
1972年 | 159篇 |
1971年 | 143篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Rizzo Manglio Miguel Bluthgen Mara Virginia Recondo Gonzalo Naveira Martin Perfetti Aldo Rizzi Florencia Kuzminin Alejandro Faura Victoria Cerini Matas Videla Alejandro Silva Carlos Lupinacci Lorena Minatta Nicols 《International journal of clinical oncology / Japan Society of Clinical Oncology》2021,26(6):1057-1064
International Journal of Clinical Oncology - Immune-checkpoint inhibitors (ICIs) are standard treatments for metastatic non-small cell lung cancer (NSCLC). Patients with poor performance status... 相似文献
3.
4.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献
5.
Evaluation of Adult versus Pediatric Transesophageal Echocardiography Probe Efficiency for Guiding Septal Puncture during Atrial Fibrillation Ablation 下载免费PDF全文
6.
7.
Francisca Morgado Mariana Batista Ana Moreno Inês Coutinho 《Pediatric dermatology》2021,38(1):191-193
We present a 6‐year‐old girl with skin hyperpigmentation, leukoplakia, and onychodystrophy, the classic mucocutaneous triad usually associated with dyskeratosis congenita. The patient also had premature graying of the hair, bone marrow failure, hepatitis, exudative retinopathy, osteopenia with multiple long bone fractures, and intracranial calcifications and brain cysts. Coats plus syndrome is a rare disease with a clinical and genetic overlap with dyskeratosis congenita. This disease is reviewed, with a focus on the pathogenesis of the genetic anomalies and its background as a telomere biology disorder. 相似文献
8.
Iria Montero Prez Laura Rodríguez‐Pazos Adriana lvarez‐Prez MªMercedes Pereiro Ferreirs Carlos Aliste Jose Manuel Suarez‐Pearanda Jaime Toribio 《Journal of cutaneous pathology》2015,42(11):889-893
Classical Kaposi sarcoma (KS) usually appears on lower extremities accompanied or preceded by local lymphedema. However, the development in areas of chronic lymphedema of the arms following mastectomy, mimicking a Stewart–Treves syndrome, has rarely been described. We report an 81‐year‐old woman who developed multiple, erythematous to purple tumors, located on areas of post mastectomy lymphedema. Histopathological examination evidenced several dermal nodules formed by spindle‐shaped cells that delimitated slit‐like vascular spaces with some red cell extravasation. Immunohistochemically, the human herpesvirus type 8 (HHV‐8) latent nuclear antigen‐1 was detected in the nuclei of most tumoral cells confirming the diagnosis of KS. Lymphedema could promote the development of certain tumors by altering immunocompetence. Although angiosarcoma (AS) is the most frequent neoplasia arising in the setting of chronic lymphedema, other tumors such as benign lymphangiomatous papules (BLAP) or KS can also develop in lymphedematous limbs. It is important to establish the difference between AS and KS because their prognosis and treatment are very different. Identification by immunohistochemistry of HHV‐8 is useful for the distinction between KS and AS or BLAP. 相似文献
9.
Huda Mohammed Alkreathy Mayson H. Alkhatib Safaa Ahmed Al Musaddi Khadijah Saeed A. Balamash Nadia Nour Osman Aftab Ahmad 《Clinical and experimental pharmacology & physiology》2019,46(5):496-505
Doxorubicin (DOX) is the most commonly used anticancer drug; however, it has limited use because prolonged administration may result in severe cardiotoxicity. Simvastatin (SIM), generally prescribed for hypercholesterolaemia, has also shown salubrious results in the monotherapy or combinational drug therapy of different cancers in various models. Nanoparticle drug delivery systems are a novel way of improving therapeutics and also improving the absorption and specificity of drugs towards tumour cells. In this study, we exploited this technology to increase drug specificity and minimize imminent adverse effects. In this study, the antitumour activity of the combination formulas of DOX and SIM, either loaded in water (DOX‐SIM‐Solution) or nanoemulsions (NEs) (DOX‐SIM‐NE), was evaluated in a Swiss albino mouse model of Ehrlich ascites carcinoma. The anticancer effect was assessed by quantifying the change in body weight, mean survival time, and percent increase in lifespan (%ILS), determining haematological and serum biochemical parameters (liver function test, kidney function test and lipid profile parameters) as well as studying the histopathological alterations in liver tissues. We observed a clear increase in %ILS of the DOX‐SIM‐Solution group (265.30) that was double the %ILS of the DOX‐SIM‐NE group (134.70). However, DOX‐SIM‐NE had a non‐toxic effect on the haematological parameters, whereas DOX‐SIM‐Solution increased the levels of haemoglobin and lymphocytes. Furthermore, the encapsulation of SIM and DOX into NEs improved the levels of all serum biochemical parameters compared to the DOX‐SIM‐Solution. A reduction in the side effects of DOX‐SIM‐NE on the liver was also established using light microscopy, which revealed that the morphologies of the hepatocytes of the mice were less affected by administration of the DOX‐SIM‐NE treatment than with the DOX‐SIM‐Solution treatment. The study showed that incorporating SIM into the DOX‐loaded‐NE formulation remarkably improved its efficiency and simultaneously reduced its adverse effects. 相似文献
10.